达芦那韦治疗HIV感染研究进展

Research progress of DRV in HIV treatment

达芦那韦(DRV)作为最新一个被批准用于治疗艾滋病病毒(HIV)感染的蛋白酶抑制剂,具有强效及高耐药基因屏障的特点,因此广泛用于HIV初治和经治的感染者,也是作为治疗失败的挽救方案中重要组成部分。此外,DRV联合拉米夫定经研究证实可以获得持续的病毒学应答。最后,已证明DRV在特殊患者群体中的安全性和有效性,特别是因为各种社会因素导致依从性差(药物成瘾,神经精神疾病等)以及既往病毒学失败或有耐药史的患者中仍发挥着重要作用。本文对达芦那韦的临床研究及应用总结、达芦那韦在治疗HIV感染方面的研究进展进行综述,为艾滋病患者的治疗提供新的方案和临床思路。

Darunavir(DRV)is the latest protease inhibitor(PI)approved for the treatment of HIV infection.It is characterized by its high genetic barrier and intrinsic antiviral potency.Therefore,it is widely used in the initial treatment and the rescue treatment for treatment failure.In addition,DRV in combination with lamivudine(3 TC)has been shown a sustained virological response.Finally,the safety and efficacy of DRV in specific populations have been demonstrated,especially in patients with poor adherence(drug addiction,mental illness,etc.)and patients with previous virological failure or history of drug resistance.This article reviews the evidences of randomized controlled trials(RCT),to provide new regime in resource-limited areas and clinical ideas for the treatment of PLWHs.